Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

MHRA greenlights donanemab for early stage Alzheimer’s disease

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease, following a thorough review of the benefits and risks.

26 Oct 2024

Researchers uncover why the TP53 gene is especially prone to mutations in cancer

Mutations in the fragile TP53 gene impair p53's tumor-suppressive functions, making it more vulnerable than other tumor suppressors.

24 Oct 2024

Researchers develop first-of-its-kind therapy to enhance heart repair after a heart attack

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a first-of-its-kind experimental therapy that has the potential to enhance heart repair following a heart attack, preventing the onset of heart failure.

24 Oct 2024

Arthritis-style immunotherapy shows promise for heart failure

A study uncovers IL-1β signaling in cardiac fibrosis, highlighting distinct fibroblast populations and promising immunotherapy strategies for heart failure.

24 Oct 2024

Immunotherapy may be an effective treatment strategy for heart failure

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy - similar to that approved by the Food and Drug Administration (FDA) to treat inflammatory conditions such as arthritis - also may be an effective treatment strategy for heart failure.

23 Oct 2024

Novel antibodies show promise for tumor targeting and RAD51 inhibition

A new research paper was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition."

21 Oct 2024

Revealing the hidden role of blood leaks in Alzheimer’s and MS

The question of what causes complex neurological diseases such as Alzheimer's or multiple sclerosis continues to confound scientists and doctors, with the unknowns standing in the way of early diagnoses and effective treatments.

18 Oct 2024

US study uncovers antiviral resistance in swine-origin influenza, urging enhanced pandemic surveillance

Researchers in the US analyzed swine-origin influenza viruses, identifying key mutations that could reduce antiviral drug effectiveness and threaten pandemic preparedness.

9 Oct 2024

Houston Methodist researchers join national consortium to develop herpesvirus vaccine

Houston Methodist researchers will be part of a national consortium funded by an up to $49 million award from the U.S. Government's Advanced Research Projects Agency for Health (ARPA-H) to develop a vaccine against two of the most common and destructive strains of herpesviruses that latently infect a majority of Americans and can lead to acute infections, multiple forms of cancer, autoimmune disease and birth defects.

3 Oct 2024

Non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer.

3 Oct 2024

Targeted drug therapy shows promise for ulcerative colitis remission

An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission.

26 Sep 2024

Researchers uncover key to combat Campylobacter infections

Bacterial infections resulting in enteritis, sometimes extra-intestinal infections such as sepsis, continue to be a global health concern.

25 Sep 2024

Drug breakthrough provides new hope for cancer patients with cachexia

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.

19 Sep 2024

Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma

A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and The University of Texas M.D. Anderson Cancer Center, have reported safety and efficacy results from a Phase 1 trial that featured a personalized vaccine to treat lymphoplasmacytic lymphoma, a rare and slow-growing type of blood cancer, according to a study published recently in Nature Communications.

19 Sep 2024

Drug-resistant SARS-CoV-2 variants found in immunocompromised patients

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population found researchers at Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University and the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

18 Sep 2024

Early intervention in pediatric-onset MS can lead to improved long-term outcomes

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term disability in multiple sclerosis (MS) patients.

18 Sep 2024

Researchers discover how oral cancer cells may block the body's immune response

Macquarie University researchers have discovered new information about how oral cancer cells may block the body's immune response. This could lead to better treatments for this aggressive disease.

18 Sep 2024

Monoclonal antibodies could help provide an answer to antimicrobial resistance

Monoclonal antibodies – treatments developed by cloning a cell that makes an antibody – could help provide an answer to the growing problem of antimicrobial resistance, say scientists.

16 Sep 2024

Review highlights mitochondrial dysfunction in cholestatic liver injury

Bile acids are essential signaling molecules derived from cholesterol metabolism in the liver and are crucial for the digestion and absorption of fats.

16 Sep 2024

New research network focuses on high-priority viruses

The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies. Currently, many of the diseases caused by these pathogens have no available vaccines or therapeutics, and investing in this research is key to preparing for potential public health crises - both in the United States and around the world. NIH's National Institute of Allergy and Infectious Diseases (NIAID) expects to commit approximately $100 million per year to fund the program, pending the availability of funds.

14 Sep 2024